I've Been Inside the Oral GLP-1 Trials. Here's What You Need to Know.

Dr. Paul S. Bradley, MD

As Scripta's Chief Medical Officer and an actively practicing clinician currently participating in GLP-1 clinical trials, I've had a front-row seat to one of the most significant shifts in obesity medicine in decades.

GLP-1 pills are dominating headlines right now, and while the excitement is warranted, there's a lot of nuance in the data that aren’t necessarily in the headlines. Here's my honest take on what's working, what's being misunderstood, and what plan sponsors should be thinking about.

Let's Start with Some History Most People Are Missing

Oral semaglutide isn't new. It's been on the market for years as Rybelsus, approved for type 2 diabetes. What's new is the weight-loss-indicated version — oral Wegovy — and the broader wave of oral GLP-1s now entering the space.

Why does that history matter? Because Rybelsus quietly struggled. Despite sharing its active compound with injectable Ozempic, it never came close to matching injectable prescription volumes. The culprit was gastrointestinal (GI) tolerability: nausea, vomiting, and stomach discomfort that were meaningfully worse in pill form than in the shot. For a lot of my diabetic patients, it simply wasn't worth it, and many couldn't work up to a therapeutic dose.

Here's what I find genuinely encouraging about the new oral weight-loss formulations: the clinical trial data suggests non-diabetic patients are significantly less susceptible to those GI side effects. In the oral Wegovy trials, patients are tolerating it well and staying on it. That's not a minor footnote — it's actually the key reason I think this new generation of oral options has a real chance where Rybelsus fell short.

How Do the Pills Actually Stack Up Against the Shots?

I'll be direct: injectable GLP-1s still win on efficacy. Apples to apples, the weight loss percentages are better with the shots. That's not a close call, and I don't want anyone walking away thinking the pills are equivalent.

That said, the comparison is more nuanced than that single number. Pills win on convenience — no needles, no refrigeration, easier to travel with. And while a once-weekly injection might sound simpler than a daily pill, some of my patients actually find it easier to build a daily habit than to remember something weekly. The oral options are also entering the market at a lower cash price than the injectables, which matters for members who aren't getting full coverage.

I also want to address the needle fear factor directly, because it comes up constantly. In my experience, nearly every patient who actually commits to trying an injectable comes away surprised. The auto-injectors today are spring-loaded, the needle is completely hidden, the whole thing is over in a second. Most patients tell me afterward it was nothing. But — and this is important — for the patients who simply will not start injectable therapy no matter what, an oral option is a genuine clinical win. Some treatment is better than none.

One more injectable development worth flagging: Novo Nordisk recently introduced a significantly higher-dose Wegovy — 7.2 mg, up from 2.4 mg — now reporting approximately 21% body weight reduction, compared to roughly 15% at the prior dose. I've written a few prescriptions at the new dose but don't have patient feedback yet. What I can say is that it meaningfully closes the gap with Zepbound's top-line numbers, which changes the competitive picture considerably.

The Foundayo Misconception I Keep Running Into

I want to be clear about something I'm seeing cause real confusion — among patients and, frankly, among some prescribers too: Foundayo is not oral Zepbound.

Zepbound, injectable tirzepatide from Eli Lilly, has produced some of the most dramatic weight loss figures in GLP-1 history — around 25% body weight reduction at its highest doses. Those are spectacular numbers. Foundayo is a different compound from Lilly's oral pipeline, and its results are not in that league. Compared directly to oral Wegovy, Foundayo comes in below it on efficacy — while landing at nearly the same cash price.

The indication gap matters too. Oral Wegovy carries a separate FDA-approved cardiac indication — approved not just for weight management, but specifically for reducing cardiovascular risk in patients with established heart disease, with trial data showing benefit beyond what weight loss alone explains. Foundayo has no approved indication beyond weight loss.

If you're a plan sponsor making formulary decisions: same price, lower efficacy, fewer covered indications. That distinction needs to be built into your strategy.

Which Patients Should Actually Be on the Oral Options?

Let me clarify the population we're really talking about, because it matters. My diabetic patients largely aren't the issue here — GLP-1 coverage for type 2 diabetes has expanded substantially as the cardiovascular and kidney disease data has become too strong for insurers to ignore. The members plan sponsors are managing are non-diabetic individuals who qualify by BMI: 27 or above with comorbidities, or 30 and above.

Within that group, I see oral GLP-1s making the strongest clinical sense in two situations. First: patients who genuinely won't initiate injectable therapy. For them, an oral pathway is a real win. Second: patients who've already achieved meaningful results on an injectable, are in a stable maintenance phase, and want to explore whether a pill could hold those results at lower cost. I've had a few of those conversations recently, and it's a reasonable discussion for the right patient at the right time.

What haven’t I seen? Anyone doing well on an injectable asking to switch back to a pill. Once patients experience the results — and get past the first shot — there's very little motivation to change what's working.

The Bigger Story That's Getting Lost

I think the oral vs. injectable debate is actually overshadowing something more important: the clinical data showing that GLP-1s treat far more than obesity, and the evidence keeps getting stronger.

I hear the skepticism — maybe you lose the weight but something else catches up with you. That hasn't been what the studies show. Injectable Wegovy now has FDA-approved indications for cardiovascular disease risk reduction and chronic kidney disease improvement, with trial data proving those benefits are additive on top of weight loss alone. Zepbound is approved for sleep apnea. Fatty liver disease — affecting an estimated 60% of Americans — continues to show meaningful improvement. These aren't side benefits. They're serious, costly conditions that GLP-1s are now proven to treat.

There's also a practical implication here that I don't think gets enough attention. Many plans that won't cover obesity treatment will cover cardiovascular disease, chronic kidney disease, and fatty liver disease. Those FDA indications open real coverage pathways for members who've been hitting walls — and understanding them can help your members access treatment they're otherwise being denied.

The Cost Is Real. So Are the Results

Yes, these are expensive medications, and I won't pretend otherwise. Someone has to cover the cost, and that's a legitimate challenge. But in my practice, more than 80% of patients I prescribe GLP-1s to tolerate them well and get meaningful results — improved blood sugar, significant weight loss, and increasingly, real improvement in their heart, kidneys, and liver. These drugs work.

The question was never really whether to cover them. It's always been how – how to make sure the right members get on the right formulation, with the right clinical oversight, at the most sustainable cost.

That means knowing which oral options actually deliver on their clinical promise — and which are trading on name recognition from injectable siblings that have nothing to do with them. It means understanding when switching from an injectable to a pill makes clinical sense, and when it's just leaving results on the table. This category is moving fast — and the plan sponsors who stay ahead of it will be the ones who approach it with rigor, not reaction.